{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004557","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.263709+00:00","generated_at":"2026-05-28T02:54:52.867086+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"EyePoint updates on DURAVYU Phase 3 wet AMD trials enrollment ahead of schedule, Phase 2 DME data expected 1Q 2025","bullets":["Phase 3 LUGANO trial for DURAVYU in wet AMD one-third enrolled; LUCIA trial tracking ahead of schedule; full enrollment target 2H 2025.","Full data from Phase 2 VERONA trial of DURAVYU in DME expected 1Q 2025; interim data showed BCVA gain +8.9 letters and CST improvement.","Cash and investments ~$370M at Dec 31, 2024; cash runway into 2027 beyond Phase 3 wet AMD topline data expected in 2026.","Appointed retina specialist Reginald J. Sanders, M.D., FASRS to Board of Directors.","Opened new 40,000+ sq ft cGMP manufacturing facility in Northbridge, MA to support commercial readiness."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004557","json":"https://secwatch.observer/filing/0000950170-25-004557.json","markdown":"https://secwatch.observer/filing/0000950170-25-004557.md","text":"https://secwatch.observer/filing/0000950170-25-004557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025004557/0000950170-25-004557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025004557/eypt-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:54:52.867086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}